Board

  • Mr. Yi Bo Shao/ Chairman & Co-Founder

    Mr. Shao is co-founder and a Managing Partner of Matrix Partners China, a leading technology venture capital firm in China, with three billion dollars under management. In addition, Mr. Shao is a co-founder of BabyTree, the leading parenting brand and community in China with over 200 million unique users a month, and a co-founder and Chairman of Nuance Biotech.  

     Prior to his current positions, Mr. Shao was the founder and CEO of EachNet, which became the dominant consumer e-commerce company in China under his leadership and was acquired by eBay (NASDAQ: EBAY) in 2003 in a landmark transaction.

    Mr. Shao was born in China and was a winner of national mathematics competitions over a dozen times during high school.  He left China when he was 17 years old for Harvard College on a full scholarship, one of the first such scholarships Harvard granted to a person from mainland China.  After receiving a BA, summa cum laude, in physics and electrical engineering from Harvard College, he worked for the Boston Consulting Group and Goldman Sachs, and received his MBA from the Harvard Business School.

     Mr. Shao is a recognized young business leader in China and the recipient of awards in China and abroad, including Young Global Leaders of the World Economic Forum and Entrepreneur of the Year 2003 by Asian Venture Capital Journal.  

  • Mark G Lotter/ CEO and Co-Founder

    BSc. Pharm,MBA.

    Mark is an industry veteran having spent the last 20 years with a number of leading MNC’s and locals layers in both China and abroad.

    Mark has spent the last 14 years in China first building the commercial operations for AZ followed by setting a venture backed pharmaceutical company – NovaMed. NovaMed was sold to a US listed company SCLN in 2011 with Mark staying on until late 2012 to lead the China operations.

    Mark has recently established a new venture backed company – Nuance Biotech, led by a globally experienced team with a strong track in China and abroad. The company is focussed on targeting development , regulatory and commercial stage assets.

  • David Su/ Board Member

    David is Founding Managing Partner of Matrix Partners China. Before Matrix, David was a founding General Partner of TDF Capital and its successor KPCB China. Between 2000 and 2008, David focused primarily on mobile internet, sofrware services and medical technology investments in China. He led TDF’s investments in Baidu.com (NASDAQ: BIDU), AAC Technologies (2018.HK), Kanghui Medical (public listed and acquired by Medtronic), P-Cube (acquired by Cisco Systems). Prior to TDF and KPCB China, David worked at Lotus for seven years, helping to build Lotus’ business in China from the ground up.

    David understands deeply the operations and sales challenges that entrepreneurs face, as he has spent a significant time in one of the most challenging industries in China in the 1990s, namely selling enterprise software while he was working for Lotus. “It was incredibly challenging, and that was even with a strong product and the backing of the global software company known for its innovation and excellence. It took immense effort to develop a nascent market from the ground up and convince customers to adopt the new products and services. The experience taught me to persevere and be open-minded when it comes to tackling key problems. We greatly appreciate the pressures that entrepreneurs go through and would like to support the entrepreneurs overcoming these key challenges,” he explained.

  • Frank K. Au/ Board Member

    Frank Au is the co-founder and Managing Partner of PacificPine, a technology growth capital firm. Mr Au has spent over 20 years covering the technology and healthcare market in China. Mr Au has spent over 15 years as an entrepreneur having founded, built and sold an independent investment banking business.

    Mr Au is the former President of China Renaissance Securities (HK), the wholly-owned broker dealer subsidiary of China Renaissance Group, the largest Internet sector focused full service investment bank in China. Prior to China Renaissance, Mr Au was the former CEO of Cowen and Company Asia and a member of Cowen’s global management committee. Prior to Cowen, Mr Au was the co-founder and President of Latitude Capital Group, a boutique M&A and private placement advisory firm with offices in Hong Kong, Beijing and Shanghai which was acquired by Cowen Group (COWN:US). Prior to co-founding Latitude, Mr Au was the former Head of Internet investment banking for Greater China at Lehman Brothers Asia. Mr Au worked for Lehman Brothers in both their New York and Hong Kong offices and served stints in the Firm’s TMT, LBO and Industrial investment banking coverage groups.

    Mr Au holds a MBA from Harvard Business School and a BA from Columbia University.


  • Dr William Brody/ Independent Board Member

    Dr. William R. Brody, President of the Salk Institute, is an acclaimed physician-scientist entrepreneur and university leader. He joined the Salk Institute on March 2, 2009 after 12 years as president of The Johns Hopkins University. Dr. Brody has over 100 publications and two U.S. patents in the field of medical imaging.

    Dr. Brody is a member of the Institute of Medicine and the National Academy of Engineering. In 2010, he was awarded the Gold Medal of the Radiological Society of North America for his contributions to medical imaging science.

    Dr. Brody received his B.S. and M.S. degrees in electrical engineering from the Massachusetts Institute of Technology, and his M.D. and Ph.D., also in electrical engineering, from Stanford University. He has been a co-founder of three medical device companies: Digirad (acquired by Agfa); Resonex (acquired by General Electric); and Biopsys Medical (acquired by Johnson and Johnson)..

    Dr. Brody serves on the board of directors of IBM, Biomed Realty Trust, and T. Rowe Price Mutual Funds, and is a member of the board of the W.M. Keck Foundation. He formerly served on the President's Foreign Intelligence Advisory Board, the Science Board of the Food and Drug Administration, the Scientific Management Review Board of the National Institutes of Health, the Corporation of the Massachusetts Institute of Technology, and the board of trustees of Stanford University.


Copyright 2017-2018 NUANCE BIOTECH INC reserved. 沪ICP备17029781号
Address: Room 2106 Ciro's Plaza, 388 Nanjing Rd.(W) Shanghai China, 200003 Email: info@nuancebiotech.cn Tel: 021-32035318
  • 首页
  • 电话
  • 留言